ACM
FATE icon

Aster Capital Management’s Fate Therapeutics FATE Stock Holding History

Aster Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$477K Buy
+176,600
New +$327K 0.1% 266

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Aster Capital Management's FATE Position: Q2 2026 in Review

Aster Capital Management opened a new position in Fate Therapeutics (FATE) in Q2 2026: 176,600 shares worth $477K. The stake represents 0.1% of the portfolio and ranks #266 among its holdings.

155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Aster Capital Management held 176,600 shares of Fate Therapeutics worth $477K as of Q2 2026.
  • Fate Therapeutics was a new Aster Capital Management position in Q2 2026.
  • Fate Therapeutics made up 0.1% of Aster Capital Management's portfolio in Q2 2026, its #266 holding.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Aster Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.